{
      "Rank": 260,
      "Acronym": [
            "ALSTEM"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture."
      ],
      "ArmGroupInterventionName": [
            "Drug: Mesenchymal stem cells isolated from Wharton's jelly"
      ],
      "ArmGroupLabel": [
            "Treatment arm"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04651855"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The objective of this study is to evaluate the safety of intrathecal administration of Wharton's Jelly Mesenchymal Stem Cells (WJMSC) and the impact on the immune system of patients with Amyotrophic Lateral Sclerosis."
      ],
      "BriefTitle": [
            "The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "National Center for Research and Development, Poland"
      ],
      "CompletionDate": [
            "April 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Amyotrophic Lateral Sclerosis"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000019636",
            "D000009422",
            "D000009468",
            "D000013118",
            "D000002493",
            "D000057177",
            "D000057165",
            "D000008659"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Neurodegenerative Diseases",
            "Nervous System Diseases",
            "Neuromuscular Diseases",
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "TDP-43 Proteinopathies",
            "Proteostasis Deficiencies",
            "Metabolic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC10",
            "BC18",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Nervous System Diseases",
            "Nutritional and Metabolic Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Sclerosis",
            "Lateral Sclerosis",
            "Amyotrophic Lateral Sclerosis",
            "Lateral Sclerosis",
            "Amyotrophic Lateral Sclerosis"
      ],
      "ConditionBrowseLeafId": [
            "M14567",
            "M18031",
            "M3176",
            "M20711",
            "M11563",
            "M15067",
            "M4894",
            "M27912",
            "M27900",
            "M10791",
            "T4699",
            "T349"
      ],
      "ConditionBrowseLeafName": [
            "Sclerosis",
            "Motor Neuron Disease",
            "Amyotrophic Lateral Sclerosis",
            "Neurodegenerative Diseases",
            "Neuromuscular Diseases",
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "TDP-43 Proteinopathies",
            "Proteostasis Deficiencies",
            "Metabolic Diseases",
            "Primary Lateral Sclerosis",
            "Amyotrophic Lateral Sclerosis"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000016472",
            "D000000690",
            "D000012598"
      ],
      "ConditionMeshTerm": [
            "Motor Neuron Disease",
            "Amyotrophic Lateral Sclerosis",
            "Sclerosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Clinical Phase: I/II\n\nPopulation: Patients with Amyotrophic Lateral Sclerosis.\n\nProject Design: One arm, non-blinded, open label study\n\nPlanned Sample Size: 20 patients\n\nInvestigational Medicinal Product: active IMP - mesenchymal stem cells isolated from Wharton's jelly\n\nScreening:\n\nThree visits on site to check the eligibility criteria (around 90, 60 and 30 days before first IMP administration)\n\nTreatment (IMP administration):\n\nEach patient will receive IMP three times: on baseline (day 0), 30 and 60 days after baseline (+/- 7 days).\n\nAdministration route: intrathecal\n\nFollow up:\n\nDuration: 18 months after first IMP administration Four on-site visits (3, 6, 9, 12 months after first IMP administration) and seven phone visits (4, 5, 7, 8, 10, 11 and 18 months after first IMP administration)"
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAdult patients (at least 18 years old)\nThe minimum patient's weight is not less than 40 kg\nDiagnosis of sporadic ALS, definite or probable, as defined by El Escorial World Federation of Neurology criteria\nHistory of ALS symptoms less than 2 years duration from the first symptoms of the disease\nMore than 6 months from diagnosis of the disease\nDisease progression at 6 past months at least 3 points during this period of time assessed in ALSFRS-R scale\nALSFRS-R scale of at least 30 at screening appointment\nForced vital capacity >70% of predicted value for age, gender and height\nTreatment with stable dose of riluzole(2x 50mg per 24h) before baseline visit (for at least 1 month)\nCapable of providing written informed consent\nAble to comply with study requirements and willing to follow all study procedures and follow-up visits\nWomen of child-bearing age and men with partners of child-bearing potential must agree to use two forms of contraceptive therapy throughout the course of the trial\nWomen of child-bearing age must undergo pregnancy test\nPolish-language native speakers or patients who are proficient in the Polish language\n\nExclusion Criteria:\n\nPregnancy or breastfeeding\nTracheostomy\nVentilator dependence\nRenal disease with creatinine >2mg/dl\nLiver disease with ALT, AST or GGTP 2-fold higher than upper normal limit\nPositive test for HBV, HCV, HIV with NAT method\nPositive tests for syphilis\nAny other clinically significant abnormalities on laboratory evaluation\nAny condition that would compromise ability of undergoing lumbar puncture\nActive systemic disease\nAutoimmune disease (Hashimoto disease under control is allowed)\nUncontrolled diabetes (HbA1c > 8%)\nPulmonary disease that could affect interpretation of spirometry\nNeurological concomitant disease\nUnstable psychiatric concomitant disease\nHigh risk of suicide\nHistory of substance abuse within past year\nHistory of malignancy, within the previous 5 years, including melanoma with exception of localized skin cancers\nAny other clinically significant medical condition that can compromise patient's safety in the opinion of the investigator\nTreatment with immunomodulatory drugs (for example immunoglobulins, corticosteroids or other immunosuppressant) in last 6 months\nParticipation in another clinical trial in last 6 months\nPrevious cellular therapy of any kind\nHypersensitivity to any component used in the cell culture\nNuchal rigidity and other signs of meningitis\nPatients on chronic anticoagulation treatment (heparin/ warfarin/acenocoumarol/(N)OAC)"
      ],
      "EnrollmentCount": [
            "20"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "Undecided"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Treatment arm"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Intrathecal administration of mesenchymal stem cells"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal stem cells isolated from Wharton's jelly"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Amyotrophic Lateral Sclerosis",
            "Stem Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 3, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "April 27, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Polski Bank Komorek Macierzystych JSC (PBKM)"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Cz\u0119stochowa"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Poland"
      ],
      "LocationFacility": [
            "JST sp. z o.o."
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [
            "42-202"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "The Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) on the Immune System of Patients With Amyotrophic Lateral Sclerosis (ALS)"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Polski Bank Komorek Macierzystych JSC (PBKM)"
      ],
      "OrgStudyId": [
            "ALSTEM"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "March 8, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "(S)AESI are defined as:\n\nMeningitis and encephalitis.\nToxic encephalopathy.\nHigh fever >39\u2070C.\nEpileptic seizures that are not connected to conditions above (meningitis, encephalitis, toxic encephalopathy, high fever)."
      ],
      "PrimaryOutcomeMeasure": [
            "The number of (S)AESI [(Serious) Adverse Event of Special Interest]"
      ],
      "PrimaryOutcomeTimeFrame": [
            "3 month FU (follow-up)"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Disease progression assessed in ALSFRS-R scale (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 48 points",
            "Pulmonary function decline assessed in spirometry (forced vital capacity)",
            "Muscle strength decline",
            "Upper motor neuron function assessed in UMNS scale (Upper Motor Neuron Scale). Best outcome 16 points, worst outcomes: 0 points and 48 points Minimum: 0 points Maximum: 48 points",
            "Cognitive function assessed in ECAS (The Edinburgh Cognitive and Behavioural ALS Screen). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 136 points",
            "Quality of life changes, assessed by EQ-5D questionnaire - standardized instrument for measuring generic health status. Higher scores mean a better outcome.",
            "The change of defined cytokines, chemokines, growth factors and pNFH level assessed in the samples of CSF",
            "The change of defined cytokines, chemokines level assessed in the samples of blood serum",
            "The change of creatinine and p75ECD level",
            "Muscle function changes, assessed based on EMG examination (Electrophysiological examination of the muscle - MUNIX - motor unit number estimation)",
            "The change of the brain visualization in MRI (T1, T2 and DTI)",
            "The number of SAE/AE and (S)AESI - defined as in Outcome 1",
            "The number of days from patients randomization to the end of the patients participation in the trial or to the one of the following:\n\nPAV (permanent assisted ventilation)\nTracheostomy\nDeath",
            "Percentage of deaths in the entire study population."
      ],
      "SecondaryOutcomeMeasure": [
            "Disease progression",
            "Pulmonary function decline",
            "Muscle strength decline",
            "Upper motor neuron function",
            "Cognitive function",
            "Quality of life changes",
            "The change of defined cytokines, chemokines, growth factors and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)",
            "The change of defined cytokines, chemokines level in blood",
            "The change of creatinine and p75ECD level in urine",
            "Muscle function changes",
            "The change of the brain visualization",
            "SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI",
            "Survival period to disease progression",
            "Mortality rate"
      ],
      "SecondaryOutcomeTimeFrame": [
            "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
            "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
            "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
            "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
            "screening and 12 month FU",
            "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
            "run-in visit (-60 day), at baseline and at 1, 2 and 6 month FU (12 month FU optional)",
            "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
            "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
            "baseline and at 1, 2, 6 and 12 month FU",
            "run-in visit (-60 day), 6 and 12 month FU",
            "18 month FU",
            "18 month FU",
            "18 month FU"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "December 2, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "April 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "December 3, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "September 30, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "December 2, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}